Related Experiment Video
Updated: Jan 27, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
Can IL-33 and Endocan be New Markers for Retinopathy of Prematurity?
Ufuk Cakir1, Cuneyt Tayman1, Cigdem Yucel2
1Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
Insights
Interleukin-33 (IL-33) and endocan show promise as sensitive biomarkers for predicting severe Retinopathy of Prematurity (ROP). Their serum levels decreased significantly after laser treatment in infants with ROP.
Area of Science:
- Neonatal ophthalmology
- Vascular biology
- Biomarker discovery
Background:
- Retinopathy of Prematurity (ROP) is a condition characterized by abnormal retinal vessel proliferation in premature infants.
- Early diagnosis and monitoring are crucial for managing ROP and preventing vision loss.
Purpose of the Study:
- To evaluate the diagnostic and follow-up potential of vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), interleukin-33 (IL-33), and endocan in Retinopathy of Prematurity.
- To identify novel biomarkers for predicting severe ROP.
Main Methods:
- A prospective cohort study involving 146 preterm infants (gestational age ≤32 weeks, birth weight ≤1500g) diagnosed with ROP.
- Measurement of VEGF, IGF-1, IL-33, and endocan levels in cord blood and serum before and after treatment in ROP and control groups.
Main Results:
- Cord blood VEGF was higher, while IGF-1 was lower in the ROP group compared to controls.
- IL-33 and endocan levels in cord blood were similar between groups.
- Serum IL-33, VEGF, and endocan levels were elevated before laser treatment and decreased significantly post-treatment.
Conclusions:
- Serum IL-33 and endocan levels may serve as sensitive novel markers for predicting severe ROP.
- These biomarkers warrant further investigation for clinical application in ROP management.
Background:
Retinopathy of Prematurity (ROP) is a pathophysiologic condition of the retina due to abnormal proliferation of retinal vessels.
Objective:
The study aimed too ascertain the importance of vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), interleukin-33 (IL-33) and endocan in the diagnosis and follow-up of ROP.
Methods:
This prospective cohort study was conducted in the neonatal intensive care unit (NICU) of Health Science University, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey, between February 2017 and August 2018. Preterm infants (gestational age (GA) of ≤32 weeks and birth weight of ≤1500 gr), diagnosed ROP were included in the study. VEGF, IGF-1, IL-33 and endocan levels were evaluated in the cord blood and in the serum before and after treatment of infants in the ROP and control groups.
Results:
A final number of 146 infants were included in the study. During the study period, 73 infants were identified as the ROP group, and 73 infants were allocated as the control group. In the ROP group, the cord blood VEGF value was higher than the control group (p <0.05). However, IGF-1 levels in the cord blood were lower in the ROP group than control (P<0.05). IL-33 and endocan values in the cord blood were similar in both control and ROP groups (p>0.05). Although serum levels of IL-33, VEGF and endocan were higher before laser treatment, these biomarkers decreased significantly after laser treatment (p <0.05).
Conclusion:
We determined that serum IL-33 and endocan levels might be suggested as sensitive novel markers for the prediction of severe ROP.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Mutations
Improving Translational Accuracy
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
piRNA - Piwi-interacting RNAs
In-vitro Mutagenesis

